Akari Therapeutics Plc (AKTX):企業の財務・戦略的SWOT分析

◆英語タイトル:Akari Therapeutics Plc (AKTX) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C15097
◆発行会社(調査会社):GlobalData
◆発行日:2019年3月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD300 ⇒換算¥44,400見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD600 ⇒換算¥88,800見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥133,200見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Akari Therapeutics Plc (Akari), formerly Celsus Therapeutics Plc is a biopharmaceutical company that develops treatments for rare and orphan autoimmune and inflammatory diseases. The company offers coversin drugs that act on complement component-C5 that helps in preventing the release of C5a and formation of C5b – 9. The company’s pipeline products include paroxysmal nocturnal hemoglobinuria, Guillain Barre Syndrome and atypical hemolytic uremic syndrome. Akari pipeline products include Coversin, Coversin LA, LTB4+C5, LTB4, LTBA LA, and bioamine inhibitors. The company operates in Switzerland, Israel, the UK and the US. Akari is headquartered in New York City, New York, the US.

Akari Therapeutics Plc Key Recent Developments

Nov 30,2018: Akari Therapeutics Announces New Data Highlighting Differentiation of Drug Candidate Coversin
Nov 30,2018: Akari Therapeutics Announces New Data Highlighting Differentiation of Drug Candidate Coversin
Nov 15,2018: Akari Therapeutics announces third quarter 2018 financial results
Sep 30,2018: Akari Therapeutics Announces New Clinical Data in Post-Transplant Thrombotic Microangiopathies Data Supports Akari s Ongoing Clinical Expansion into a Range of Orphan Autoinflammatory Diseases That Are Either Mediated by Complement C5 or Have Synchronous

This comprehensive SWOT profile of Akari Therapeutics Plc provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Akari Therapeutics Plc including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

Akari Therapeutics Plc – Key Information
Akari Therapeutics Plc – Overview
Akari Therapeutics Plc – Key Employees
Akari Therapeutics Plc – Key Employee Biographies
Akari Therapeutics Plc – Key Operational Heads
Akari Therapeutics Plc – Major Products and Services
Akari Therapeutics Plc – History
Akari Therapeutics Plc – Company Statement
Akari Therapeutics Plc – Locations And Subsidiaries
Akari Therapeutics Plc – Key Manufacturing facilities
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

Akari Therapeutics Plc – Business Description
Akari Therapeutics Plc – Corporate Strategy
Akari Therapeutics Plc – SWOT Analysis
SWOT Analysis – Overview
Akari Therapeutics Plc – Strengths
Akari Therapeutics Plc – Weaknesses
Akari Therapeutics Plc – Opportunities
Akari Therapeutics Plc – Threats
Akari Therapeutics Plc – Key Competitors

Section 3 – Company Financial Performance Charts

Akari Therapeutics Plc – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

Akari Therapeutics Plc, Key Information
Akari Therapeutics Plc, Key Ratios
Akari Therapeutics Plc, Share Data
Akari Therapeutics Plc, Major Products and Services
Akari Therapeutics Plc, History
Akari Therapeutics Plc, Key Employees
Akari Therapeutics Plc, Key Employee Biographies
Akari Therapeutics Plc, Key Operational Heads
Akari Therapeutics Plc, Other Locations
Akari Therapeutics Plc, Subsidiaries
Akari Therapeutics Plc, Key Manufacturing facilities
Akari Therapeutics Plc, Key Competitors
Akari Therapeutics Plc, SWOT Analysis
Akari Therapeutics Plc, Ratios based on current share price
Akari Therapeutics Plc, Annual Ratios
Akari Therapeutics Plc, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures

Akari Therapeutics Plc, Performance Chart
Akari Therapeutics Plc, Ratio Charts

★海外企業調査レポート[Akari Therapeutics Plc (AKTX):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Wentworth Resources Ltd (WRL):石油・ガス:M&Aディール及び事業提携情報
    Summary Wentworth Resources Ltd (Wentworth) is an independent upstream oil and gas company. It conducts the exploration and development of oil and natural gas reserves. The company has producing gas assets in Tanzania, oil and gas exploration activities in both Mozambique and Tanzania. The company o …
  • Windtree Therapeutics Inc:企業の戦略・SWOT・財務分析
    Windtree Therapeutics Inc - Strategy, SWOT and Corporate Finance Report Summary Windtree Therapeutics Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Syncardia Systems LLC:企業の戦略的SWOT分析
    Syncardia Systems LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • G. Pohl-Boskamp GmbH & Co KG:製薬・医療:M&Aディール及び事業提携情報
    Summary G. Pohl-Boskamp GmbH & Co KG (Pohl-Boskamp) is a developer of medicines and medical devices. The company offers products which include GeloMyrtol forte, GeloRevoice, GeloSitin Nasenpflege, GeloSitin Nasal Care, GeloBronchial-Saft, GeloDurat-Salbe, GeloDuratInhalator N, Laxopol, Nitrolingual …
  • CytoSorbents Corp (CTSO)-医療機器分野:企業M&A・提携分析
    Summary CytoSorbents Corp (CytoSorbents), formerly MedaSorb Technologies Corp, is a critical care immunotherapy company that specializes in the development of blood purification products. Its flagship product, CytoSorb is an extracorporeal cytokine adsorber that is designed to control extreme system …
  • Pregis LLC.:企業の戦略・SWOT・財務情報
    Pregis LLC. - Strategy, SWOT and Corporate Finance Report Summary Pregis LLC. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • De’Longhi S.p.A. (DLG):企業の財務・戦略的SWOT分析
    De'Longhi S.p.A. (DLG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Lyft Inc (LYFT):企業の財務・戦略的SWOT分析
    Lyft Inc (LYFT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Linamar Corporation:企業の戦略・SWOT・財務分析
    Linamar Corporation - Strategy, SWOT and Corporate Finance Report Summary Linamar Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Astute Medical Inc-製薬・医療分野:企業M&A・提携分析
    Summary Astute Medical Inc (Astute Medical) is a healthcare service provider that provides diagnostic products. The company offers biomarker products such as nephro check test and astute meter. Its products are used in the field of identifying and validating biomarkers of acute kidney injury through …
  • China New Borun Corporation:企業の戦略・SWOT・財務分析
    China New Borun Corporation - Strategy, SWOT and Corporate Finance Report Summary China New Borun Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • GenapSys Inc:医療機器:M&Aディール及び事業提携情報
    Summary GenapSys Inc (GenapSys) is engaged in the development of DNA sequencing technologies for applied genomic testing, and medical sequencing. The company offers a Gene Electronic Nano-Integrated Ultra-Sensitive (GENIUS) technology platform that identifies the genome and delivers the insights of …
  • AB-Biotics SA (ABB):製薬・医療:M&Aディール及び事業提携情報
    Summary AB-Biotics SA (AB-Biotics) is a provider of probiotics, pipeline products, specialty dietary supplements, and other functional ingredients. The company’s products comprise iron-containing ingredients, lactobacillus plantarum, probiotic products, gastrointestinal treatment products, proprieta …
  • Fagron NV (FAGR)-医療機器分野:企業M&A・提携分析
    Summary Fagron NV (Fagron), formerly Arseus NV is a provider of pharmaceutical compounding solutions. The company provides compounding essentials, trademarks, and pharma services to pharmacies, hospitals and clinics. Its compounding services provide customized pharmaceutical products for specific pa …
  • Daihatsu Motor Co Ltd:戦略・SWOT・企業財務分析
    Daihatsu Motor Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Daihatsu Motor Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • CryoLife Inc (CRY):医療機器:M&Aディール及び事業提携情報
    Summary CryoLife Inc (CryoLife) is a provider of biosurgical devices and implantable living tissues for cardiac and vascular surgical procedures. The company’s portfolio enlists preserved human cardiac allografts, vascular allografts, surgical adhesives and sealants, heart valves, carbon dioxide dif …
  • Skadden, Arps, Slate, Meagher & Flom LLP and Affiliates:企業の戦略・SWOT・財務分析
    Skadden, Arps, Slate, Meagher & Flom LLP and Affiliates - Strategy, SWOT and Corporate Finance Report Summary Skadden, Arps, Slate, Meagher & Flom LLP and Affiliates - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the compan …
  • IMI Plc (IMI):企業の財務・戦略的SWOT分析
    IMI Plc (IMI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • Bechtle AG (BC8):企業の財務・戦略的SWOT分析
    Summary Bechtle AG (Bechtle) is an information technology (IT) products retailer. The company offers various productswhich include notebooks, tablets, smartphones, mobile phones, wearables, power banks, spare parts, accessories, monitors, public display, projectors, input devises, scanners, barcode …
  • FluoroPharma Medical Inc:医療機器:M&Aディール及び事業提携情報
    Summary FluoroPharma Medical Inc (FluoroPharma) is a molecular imaging company that develops and commercialize proprietary medical diagnostic imaging products. The company develops breakthrough positron emission tomography imaging agents for the assessment and detection of acute and chronic forms of …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆